Top

Published in:

01-04-2020 | Gastric Cancer | Original Article

The Impact of MicroRNA-133a on Prognosis and Clinicopathological Parameters for Digestive System Cancers: a Comprehensive Study Based on Meta-Analysis and TCGA Database

Authors: Wei Zhu, Xiaoliang Ji

Published in: Pathology & Oncology Research | Issue 2/2020

Abstract

We conducted a meta-analysis on the impact of microRNA-133a (miR-133a) on digestive system cancers, and verified the results through The Cancer Genome Atlas (TCGA). Relevant studies were searched in English and Chinese database and meta-analysis was performed using Stata 12.0. The corresponding information of miR-133a and digestive system cancers were obtained from TCGA database and analysis was performed using SPSS. Increased miR-133a expression was linked with favorable overall survival (OS) in digestive system cancers (HR = 0.539, 95% CI: 0.416–0.698, P < 0.001), digestive tract cancers (HR =0.558, 95% CI: 0.406–0.767, P < 0.001), esophageal squamous cell carcinoma (ESCC) (HR = 0.427, 95% CI: 0.265–0.690, P = 0.001) and gastric cancer (HR = 0.541, 95% CI: 0.385–0.761, P < 0.001). The expression of miR-133a was significantly lower in cancer tissue compared with adjacent tissue for ESCC (P < 0.001), gastric cancer (P < 0.001), colorectal cancer (P < 0.001) and hepatocellular carcinoma (P = 0.002). Meanwhile, the area under the ROC curve (AUC) value for miR-133a was 0.836, 0.888, and 0.99 in ESCC, gastric cancer and colorectal cancer. MiR-133a is a tumor suppressor with prognostic and diagnostic values for digestive system cancers. High miR-133a expression was associated with better prognosis and less adverse clinicopathological parameters. More research should be performed to test these findings.

Available only for authorised users

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262 CrossRefPubMed

Pourhoseingholi MA, Vahedi M, Baghestani AR (2015) Burden of gastrointestinal cancer in Asia; an overview. Gastroenterol Hepatol Bed Bench 8(1):19–27PubMedPubMedCentral

Yuequan J, Shifeng C, Bing Z (2010) Prognostic factors and family history for survival of esophageal squamous cell carcinoma patients after surgery. Ann Thorac Surg 90(3):908–913. https://doi.org/10.1016/j.athoracsur.2010.05.060 CrossRefPubMed

Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, Lin C, Socci ND, Hermida L, Fulci V, Chiaretti S, Foa R, Schliwka J, Fuchs U, Novosel A, Muller RU, Schermer B, Bissels U, Inman J, Phan Q, Chien M, Weir DB, Choksi R, De Vita G, Frezzetti D, Trompeter HI, Hornung V, Teng G, Hartmann G, Palkovits M, Di Lauro R, Wernet P, Macino G, Rogler CE, Nagle JW, Ju J, Papavasiliou FN, Benzing T, Lichter P, Tam W, Brownstein MJ, Bosio A, Borkhardt A, Russo JJ, Sander C, Zavolan M, Tuschl T (2007) A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129(7):1401–1414. https://doi.org/10.1016/j.cell.2007.04.040 CrossRefPubMedPubMedCentral

Gao SH, Liu J, Zhang HJ, Zhao N, Zhang J (2016) Low miR-133a expression is a predictor of outcome in patients with esophageal squamous cell cancer. Eur Rev Med Pharmacol Sci 20(18):3788–3792PubMed

Li CY, Liang GY, Yao WZ, Sui J, Shen X, Zhang YQ, Peng H, Hong WW, Ye YC, Zhang ZY, Zhang WH, Yin LH, Pu YP (2017) Identification and functional characterization of microRNAs reveal a potential role in gastric cancer progression. Clin Transl Oncol 19(2):162–172. https://doi.org/10.1007/s12094-016-1516-y CrossRefPubMed

Wan TM, Lam CS, Ng L, Chow AK, Wong SK, Li HS, Man JH, Lo OS, Foo D, Cheung A, Yau T, Poon JT, Poon RT, Law WL, Pang RW (2014) The clinicopathological significance of miR-133a in colorectal cancer. Dis Markers 2014:919283–919288. https://doi.org/10.1155/2014/919283 CrossRefPubMedPubMedCentral

Qin Y, Dang X, Li W, Ma Q (2013) miR-133a functions as a tumor suppressor and directly targets FSCN1 in pancreatic cancer. Oncol Res 21(6):353–363. https://doi.org/10.3727/096504014x14024160459122 CrossRefPubMed

Krieg A, Riemer JC, Telan LA, Gabbert HE, Knoefel WT (2015) CXCR4--a prognostic and Clinicopathological biomarker for pancreatic ductal adenocarcinoma: a meta-analysis. PLoS One 10(6):e0130192. https://doi.org/10.1371/journal.pone.0130192 CrossRefPubMedPubMedCentral

10.

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. https://doi.org/10.1007/s10654-010-9491-z CrossRef

11.

Riley RD, Elia EG, Malin G, Hemming K, Price MP (2015) Multivariate meta-analysis of prognostic factor studies with multiple cut-points and/or methods of measurement. Stat Med 34(17):2481–2496. https://doi.org/10.1002/sim.6493 CrossRefPubMedPubMedCentral

12.

Suzuki S, Yokobori T, Tanaka N, Sakai M, Sano A, Inose T, Sohda M, Nakajima M, Miyazaki T, Kato H, Kuwano H (2012) CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncol Rep 28(2):465–472. https://doi.org/10.3892/or.2012.1831 CrossRefPubMed

13.

Akanuma N, Hoshino I, Akutsu Y, Murakami K, Isozaki Y, Maruyama T, Yusup G, Qin W, Toyozumi T, Takahashi M, Suito H, Hu X, Sekino N, Matsubara H (2014) MicroRNA-133a regulates the mRNAs of two invadopodia-related proteins, FSCN1 and MMP14, in esophageal cancer. Br J Cancer 110(1):189–198. https://doi.org/10.1038/bjc.2013.676 CrossRefPubMed

14.

Chen G, Peng J, Zhu W, Tao G, Song Y, Zhou X, Wang W (2014) Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy. Med Oncol 31(11):263. https://doi.org/10.1007/s12032-014-0263-6 CrossRefPubMed

15.

Cheng Z, Liu F, Wang G, Li Y, Zhang H, Li F (2014) miR-133 is a key negative regulator of CDC42-PAK pathway in gastric cancer. Cell Signal 26(12):2667–2673. https://doi.org/10.1016/j.cellsig.2014.08.012 CrossRefPubMed

16.

Wang LL, Du LT, Li J, Liu YM, Qu AL, Yang YM, Zhang X, Zheng GX, Wang CX (2014) Decreased expression of miR-133a correlates with poor prognosis in colorectal cancer patients. World J Gastroenterol 20(32):11340–11346. https://doi.org/10.3748/wjg.v20.i32.11340 CrossRefPubMedPubMedCentral

17.

Zhang W, Liu K, Liu S, Ji B, Wang Y, Liu Y (2015) MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma. Tumour Biol 36(12):9779–9788. https://doi.org/10.1007/s13277-015-3749-8 CrossRefPubMed

18.

Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11):857–866. https://doi.org/10.1038/nrc1997 CrossRefPubMed

19.

Kaluzna EM (2014) MicroRNA-155 and microRNA-196b: promising biomarkers in hepatitis C virus infection? Rev Med Virol 24(3):169–185. https://doi.org/10.1002/rmv.1785 CrossRefPubMed

20.

Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, Peng ZH (2012) Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol 138(1):153–161. https://doi.org/10.1007/s00432-011-1076-z CrossRefPubMed

21.

Godfrey AC, Xu Z, Weinberg CR, Getts RC, Wade PA, DeRoo LA, Sandler DP, Taylor JA (2013) Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the sister study cohort. Breast Cancer Res 15(3):R42. https://doi.org/10.1186/bcr3428 CrossRefPubMedPubMedCentral

22.

Wang LK, Hsiao TH, Hong TM, Chen HY, Kao SH, Wang WL, Yu SL, Lin CW, Yang PC (2014) MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma. PLoS One 9(5):e96765. https://doi.org/10.1371/journal.pone.0096765 CrossRefPubMedPubMedCentral

23.

Li S, Xiao FY, Shan PR, Su L, Chen DL, Ding JY, Wang ZQ (2015) Overexpression of microRNA-133a inhibits ischemia-reperfusion-induced cardiomyocyte apoptosis by targeting DAPK2. J Hum Genet 60(11):709–716. https://doi.org/10.1038/jhg.2015.96 CrossRefPubMed

24.

Ji F, Zhang H, Wang Y, Li M, Xu W, Kang Y, Wang Z, Wang Z, Cheng P, Tong D, Li C, Tang H (2013) MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1. Bone 56(1):220–226. https://doi.org/10.1016/j.bone.2013.05.020 CrossRefPubMed

25.

Fujiwara T, Katsuda T, Hagiwara K, Kosaka N, Yoshioka Y, Takahashi RU, Takeshita F, Kubota D, Kondo T, Ichikawa H, Yoshida A, Kobayashi E, Kawai A, Ozaki T, Ochiya T (2014) Clinical relevance and therapeutic significance of microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells. Stem Cells 32(4):959–973. https://doi.org/10.1002/stem.1618 CrossRefPubMed

26.

Nohata N, Hanazawa T, Kikkawa N, Mutallip M, Fujimura L, Yoshino H, Kawakami K, Chiyomaru T, Enokida H, Nakagawa M, Okamoto Y, Seki N (2011) Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int J Oncol 38(1):209–217PubMed

27.

Zhao L, Wang H, Liu C, Liu Y, Wang X, Wang S, Sun X, Li J, Deng Y, Jiang Y, Ding Y (2010) Promotion of colorectal cancer growth and metastasis by the LIM and SH3 domain protein 1. Gut 59(9):1226–1235. https://doi.org/10.1136/gut.2009.202739 CrossRefPubMed

28.

Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N, Nakagawa M (2010) miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 102(5):883–891. https://doi.org/10.1038/sj.bjc.6605570 CrossRefPubMedPubMedCentral

29.

Xiao J, Zou Y, Lu X, Xie B, Yu Q, He B, He B, Chen Q (2016) Prognostic value of decreased microRNA-133a in solid cancers: a meta-analysis. OncoTargets Ther 9:5771–5779. https://doi.org/10.2147/ott.s112358 CrossRef

30.

Zhao Y, Huang J, Zhang L, Qu Y, Li J, Yu B, Yan M, Yu Y, Liu B, Zhu Z (2014) MiR-133b is frequently decreased in gastric cancer and its overexpression reduces the metastatic potential of gastric cancer cells. BMC Cancer 14:34. https://doi.org/10.1186/1471-2407-14-34 CrossRefPubMedPubMedCentral

31.

Li X, Wan X, Chen H, Yang S, Liu Y, Mo W, Meng D, Du W, Huang Y, Wu H, Wang J, Li T, Li Y (2014) Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer. Clin Cancer Res 20(9):2312–2325. https://doi.org/10.1158/1078-0432.ccr-13-1588 CrossRefPubMed

32.

Chen XN, Wang KF, Xu ZQ, Li SJ, Liu Q, Fu DH, Wang X, Wu B (2014) MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1. Cancer Cell Int 14:70. https://doi.org/10.1186/s12935-014-0070-3 CrossRefPubMedPubMedCentral

33.

Qiu T, Zhou X, Wang J, Du Y, Xu J, Huang Z, Zhu W, Shu Y, Liu P (2014) MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. FEBS Lett 588(7):1168–1177. https://doi.org/10.1016/j.febslet.2014.02.054 CrossRefPubMed

34.

Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M, Matsubara H (2010) miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 127(12):2804–2814. https://doi.org/10.1002/ijc.25284 CrossRefPubMed

35.

Zhou Y, Wu D, Tao J, Qu P, Zhou Z, Hou J (2013) MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. Scand J Urol 47(5):423–432. https://doi.org/10.3109/00365599.2012.748821 CrossRefPubMed

Title: The Impact of MicroRNA-133a on Prognosis and Clinicopathological Parameters for Digestive System Cancers: a Comprehensive Study Based on Meta-Analysis and TCGA Database
Authors: Wei Zhu
Xiaoliang Ji
Publication date: 01-04-2020
Publisher: Springer Netherlands
Keywords: Gastric Cancer
Hepatocellular Carcinoma
Gastric Cancer
Hepatocellular Carcinoma
Colorectal Cancer
Colorectal Cancer
Published in: Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-019-00619-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Preliminary Study on Selected Markers of Oxidative Stress, Inflammation and Angiogenesis in Patients with Bladder Cancer

Sevoflurane Inhibits Glioma Cells Proliferation and Metastasis through miRNA-124-3p/ROCK1 Axis

Selective Inhibition of HIF1α Expression by ZnSO4 Has Antitumoral Effects in Human Melanoma

Identification and Verification of Two Novel Differentially Expressed Proteins from Non-neoplastic Mucosa and Colorectal Carcinoma Via iTRAQ Combined with Liquid Chromatography-Mass Spectrometry

The Development and Application of Virtual Reality Animation Simulation Technology: Take Gastroscopy Simulation System as an Example

KIBRA Team Up with Partners to Promote Breast Cancer Metastasis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer